

Standalone Information		For the Quarter ended on		For the Period ended on		For the year ended on
Sr. No.	PARTICULARS	31.12.2010 (UNAUDITED)	31.12.2009 (UNAUDITED)	31.12.2010 (UNAUDITED)	31.12.2009 (UNAUDITED)	31st March 10 (AUDITED)
	Revenue	3,524.72	6,361.41	12,211.87	14,991.30	20,116.58
	Profit Before Tax from Ordinary activities	(382.91)	212.77	(55.94)	(485.36)	62.67
	Profit After Tax from Ordinary activities	(382.91)	112.77	(55.94)	(585.36)	28.98

Notes:

- 1 The above results have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 14.02.2011.
- 2 The Company will consider the effect of Deferred Tax Assets/(Liabilities) - AS 22 in the audited accounts at the year end.
- 3 The company has on 28th July, 2010 entered into a Business Transfer Agreement with Kores(India) Limited for sale and transfer of its Active Pharmaceutical Ingredients (API) business together with its Manufacturing facilities located at plot Nos.A-88 and D-10,MIDC, Kurkumbh, Pune, Maharashtra.
- 4 The Company has issued USD 50 Million zero coupon Foreign Currency Convertible Bonds in November-2005. No Provision have been made during the year for foreign exchange difference account and for Yield to Maturity(YTM) in case of Foreign Currency Convertible Bond. The bonds have become due for redemption on 09th November,2010 and were not redeemed. The Company is in constructive conversations with bond holders for the restructuring of the bonds.
- 5 The current outstanding of bonds is USD 43,999,000. The accredited value of bonds with YTM is 145.20% of the principle value.
- 5 The Consolidated Financial Statements Include Financial Statements of the subsidiaries Nova Pharmaceuticals Australasia Pty Ltd and Marksans Pharma (U.K.) Limited.
- 6 The Consolidated Financial Statements are prepared in accordance with Accounting Standard 21 "Consolidated Financial Statement" issued by the Institute of Chartered Accountants of India.
- 7 The Company is primarily engaged in a single business segment of Manufacturing & Marketing of Pharmaceutical Formulations.
- 8 There were no pending investor complaints at the beginning and end of the Quarter. The Company has not received any investor complaint during the Quarter.
- 9 Previous year's figures have been re-grouped/re-classified, wherever necessary, so as to make them comparable with the current year's figures.

Place: Mumbai.
Date: 14.02.2011
Visit us at www.marksanspharma.com

For MARKSANS PHARMA LIMITED

MARK SALDANHA
Managing Director.

